Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PEP-010,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PEP-Therapy Wins FDA Orphan Drug Tag for PEP-010 in Pancreatic Cancer
Details : PEP-010, is currently undergoing early-stage clinical trials in combination with paclitaxel/gemcitabine for treating advanced/metastatic ovarian cancer & metastatic pancreatic ductal adenocarcinoma.
Product Name : PEP-010
Product Type : Peptide
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : PEP-010,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PEP-010,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PEP-Therapy Doses First Patients in Phase Ib Trial Of PEP-010 for Cancers
Details : PEP-010 is in early trials with Paclitaxel/Gemcitabine for advanced ovarian cancer and pancreatic ductal adenocarcinoma.
Product Name : PEP-010
Product Type : Peptide
Upfront Cash : Inapplicable
April 25, 2024
Lead Product(s) : PEP-010,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PEP-Therapy Extends Series-A Financing, Raising a Total of €5.4 Million
Details : PEP-010 is the first of a new class of therapeutic peptides based on PEP-Therapy's innovative Cell Penetrating & Interfering Peptide (CP&IP) technology.
Product Name : PEP-010
Product Type : Peptide
Upfront Cash : Undisclosed
July 19, 2021
Details : PEP-010 is the first of a new class of therapeutic peptides based on PEP-Therapy’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology for the treatment of advanced solid tumors.
Product Name : PEP-010
Product Type : Peptide
Upfront Cash : Inapplicable
May 10, 2021
Lead Product(s) : PEP-010
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Italian Angels for Growth
Deal Size : $3.5 million
Deal Type : Series A Financing
Details : PEP-Therapy will use the funds to progress the clinical development of PEP-010, PEP-Therapy's lead Cell Penetrating & Interfering Peptide (CP&IP), for the treatment of advanced solid tumors.
Product Name : PEP-010
Product Type : Peptide
Upfront Cash : Undisclosed
April 22, 2021
Lead Product(s) : PEP-010
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Italian Angels for Growth
Deal Size : $3.5 million
Deal Type : Series A Financing
Details : PEP-010 is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.
Product Name : PEP-010
Product Type : Peptide
Upfront Cash : Inapplicable
March 16, 2021